- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 275/03 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 275/03
Total number of patents in this class: 167
10-year publication summary
|
8
|
8
|
17
|
17
|
11
|
13
|
14
|
10
|
10
|
6
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Blade Therapeutics, Inc. | 19 |
7 |
| Allergan, Inc. | 2313 |
6 |
| Bayer Cropscience AG | 1983 |
6 |
| Abbvie Inc. | 1817 |
5 |
| Bayer AG | 3401 |
4 |
| Eli Lilly and Company | 3926 |
4 |
| Epizyme, Inc. | 375 |
4 |
| Romark Laboratories L.C. | 49 |
4 |
| Disarm Therapeutics, Inc. | 50 |
4 |
| Inipharm, Inc. | 30 |
4 |
| BASF SE | 21098 |
3 |
| Board of Regents, The University of Texas System | 5946 |
3 |
| Duke University | 3125 |
3 |
| Alexion Pharmaceuticals, Inc. | 639 |
3 |
| Beijing Tianqing Chemicals Co. Ltd. | 7 |
3 |
| Dompé Farmaceutici S.p.A. | 278 |
3 |
| IsoPlexis Corporation | 117 |
3 |
| Elanco Tiergesundheit AG | 416 |
3 |
| Theravance Biopharma R&D IP, LLC | 453 |
3 |
| Calico Life Sciences LLC | 104 |
3 |
| Other owners | 89 |